Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pseudomyxoma Peritonei 1Neoplasms, Cystic, Mucinous, and Serous 1Neoplasms 1Adenocarcinoma, Mucinous 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Bromelains × Clear all
NCT03976973 2022-03-15

BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei

Mucpharm Pty Ltd

Phase 2 Unknown
62 enrolled

Adenocarcinoma, Mucinous, Pseudomyxoma Peritonei, Neoplasms, Cystic, Mucinous, and Serous

NCT02340845 2015-01-19

Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans

Oeyama-Moto Cancer Research Foundation

Phase 2 Unknown
100 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡